GSK-3 inhibition induced anti-survival effects in pancreatic cancer cells, associated with downregulation of NF-κB activity and reduced expression of anti-apoptotic target genes such as XIAP, BcL-XL, and cyclin D1 [14]. Here, BCL2L1 is linked to pancreatic neoplasm.